ESSA Pharma Inc
NASDAQ:EPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Huafon Chemical Co Ltd
SZSE:002064
|
CN |
|
Coor Service Management Holding AB
STO:COOR
|
SE |
ESSA Pharma Inc
EPS (Diluted)
ESSA Pharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
EPS (Diluted)
$0
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
26%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
EPS (Diluted)
-CA$1
|
CAGR 3-Years
34%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
EPS (Diluted)
$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
EPS (Diluted)
-$4
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-15%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
7%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ESSA Pharma Inc
Glance View
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
See Also
What is ESSA Pharma Inc's EPS (Diluted)?
EPS (Diluted)
-0.6
USD
Based on the financial report for Jun 30, 2025, ESSA Pharma Inc's EPS (Diluted) amounts to -0.6 USD.
What is ESSA Pharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
26%
Over the last year, the EPS (Diluted) growth was 10%. The average annual EPS (Diluted) growth rates for ESSA Pharma Inc have been 13% over the past three years , 12% over the past five years , and 26% over the past ten years .
